Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 15/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442390 | 1.00 | NPC1 (0.55) | NPC1RAB9AAKR1C3AKR1C1VCP | |
| SCHEMBL5203627 | 0.87 | NPC1 (0.45) | NPC1RAB9AAKR1C3AKR1C1VCP | |
| SCHEMBL5203636 | 0.87 | NPC1 (0.45) | NPC1RAB9AAKR1C3AKR1C1VCP | |
| SCHEMBL440195 | 0.85 | TDP1 (0.43) | NPC1RAB9AVCPADORA3ADORA2A | |
| SCHEMBL407689 | 0.85 | TDP1 (0.43) | NPC1RAB9AVCPADORA3ADORA2A | |
| SCHEMBL5206565 | 0.84 | KCNH2 (0.47) | NPC1RAB9AVCP | |
| SCHEMBL5205158 | 0.84 | KCNH2 (0.47) | NPC1RAB9AVCP | |
| SCHEMBL14608992 | 0.84 | KCNH2 (0.47) | NPC1RAB9AVCP | |
| Hydrochloric Acid SCHEMBL9407998 | 0.83 | NPC1 (0.50) | NPC1RAB9A | |
| SCHEMBL242610 | 0.80 | ADORA1 (0.52) | NPC1RAB9AADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | NPC1 142/4885RAB9A 1525/4885AKR1C3 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.